Fei Kang

2.6k total citations
99 papers, 1.8k citations indexed

About

Fei Kang is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Biomedical Engineering. According to data from OpenAlex, Fei Kang has authored 99 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Radiology, Nuclear Medicine and Imaging, 31 papers in Oncology and 28 papers in Biomedical Engineering. Recurrent topics in Fei Kang's work include Peptidase Inhibition and Analysis (22 papers), Radiopharmaceutical Chemistry and Applications (18 papers) and Nanoplatforms for cancer theranostics (13 papers). Fei Kang is often cited by papers focused on Peptidase Inhibition and Analysis (22 papers), Radiopharmaceutical Chemistry and Applications (18 papers) and Nanoplatforms for cancer theranostics (13 papers). Fei Kang collaborates with scholars based in China, United States and Singapore. Fei Kang's co-authors include Jing Wang, Xiaohong Chen, Mingru Zhang, Weidong Yang, Lisen Lin, Zhantong Wang, Liangcan He, Weijing Yang, Rui Tian and Hongzhang Deng and has published in prestigious journals such as Advanced Materials, Nature Communications and Neuron.

In The Last Decade

Fei Kang

88 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fei Kang China 25 739 500 472 418 386 99 1.8k
John A. Ronald Canada 19 454 0.6× 345 0.7× 263 0.6× 330 0.8× 669 1.7× 70 1.8k
Vasileios Askoxylakis Germany 25 854 1.2× 477 1.0× 390 0.8× 754 1.8× 735 1.9× 49 2.5k
Wendy Kelder Netherlands 15 902 1.2× 304 0.6× 471 1.0× 548 1.3× 393 1.0× 31 2.2k
Michael J. Eblan United States 13 878 1.2× 268 0.5× 424 0.9× 342 0.8× 460 1.2× 26 2.2k
Carsten H. Nielsen Denmark 23 592 0.8× 496 1.0× 181 0.4× 391 0.9× 657 1.7× 53 1.9k
Antonello E. Spinelli Italy 23 501 0.7× 665 1.3× 279 0.6× 183 0.4× 398 1.0× 93 1.7k
Everett J. Moding United States 17 472 0.6× 402 0.8× 471 1.0× 388 0.9× 435 1.1× 51 1.6k
Meenal Datta United States 17 956 1.3× 188 0.4× 322 0.7× 765 1.8× 569 1.5× 42 2.6k
Jane Sosabowski United Kingdom 29 559 0.8× 787 1.6× 209 0.4× 793 1.9× 584 1.5× 67 2.2k
Jianwu Xie United States 22 780 1.1× 313 0.6× 187 0.4× 749 1.8× 701 1.8× 36 2.2k

Countries citing papers authored by Fei Kang

Since Specialization
Citations

This map shows the geographic impact of Fei Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei Kang more than expected).

Fields of papers citing papers by Fei Kang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fei Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei Kang. The network helps show where Fei Kang may publish in the future.

Co-authorship network of co-authors of Fei Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Fei Kang. A scholar is included among the top collaborators of Fei Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fei Kang. Fei Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Xiaobo, Jianyang Fang, Fei Kang, et al.. (2025). Exploration of Bicyclic Peptide Ligands for Immune-Specific PET Imaging: Targeting Tumor PD-L1 with [18F]AlF-BCY10959. Molecular Pharmaceutics. 22(6). 3456–3467. 1 indexed citations
2.
Li, Xiang, Xiaohui Lv, Tingting Han, et al.. (2024). Surgical evidence-based comparison of [68Ga]Ga-FAPI-04 PET and MRI-DWI for assisting debulking surgery in ovarian cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 51(6). 1773–1785. 5 indexed citations
3.
4.
Guo, Kun, Yuan Yuan Wang, Yang Wang, et al.. (2024). Evaluating the Efficacy of CortexID Quantitative Analysis in Localization of the Epileptogenic Zone in Patients with Temporal Lobe Epilepsy. Neurology and Therapy. 13(5). 1403–1414. 2 indexed citations
5.
6.
Kang, Fei, Wenhui Ma, Guiyu Li, et al.. (2024). Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System. Journal of Nuclear Medicine. 65(8). 1313–1319.
7.
Li, Hong, et al.. (2024). Metformin as a strategy against false positives in 18F-FDG PET/CT due to inflammation. Heliyon. 10(23). e40269–e40269.
8.
Yang, Wei‐Dong, Fei Kang, Yue Chen, et al.. (2024). Landscape of Nuclear Medicine in China and Its Progress on Theranostics. Journal of Nuclear Medicine. 65(Supplement 1). 29S–37S. 11 indexed citations
9.
Kang, Fei, Meng Niu, Zijian Zhou, et al.. (2024). Spatiotemporal Concurrent PARP Inhibitor Sensitization Based on Radiation‐Responsive Nanovesicles for Lung Cancer Chemoradiotherapy. Advanced Healthcare Materials. 13(28). e2400908–e2400908. 5 indexed citations
10.
Zhang, Mingru, Fei Kang, Tong Xing, et al.. (2024). First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [68Ga]Ga-HER2 Affibody. European Journal of Nuclear Medicine and Molecular Imaging. 51(6). 1713–1724. 12 indexed citations
11.
Xiang, Jie, Jingrong Tang, Fei Kang, et al.. (2024). Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson’s and Alzheimer’s disease co-pathology and behavior impairments. Neuron. 112(21). 3585–3601.e5. 29 indexed citations
12.
Li, Xiang, Jingyi Wang, Guiyu Li, et al.. (2023). First-in-Humans PET Imaging ofKRASG12CMutation Status in Non–Small Cell Lung and Colorectal Cancer Patients Using [18F]PFPMD. Journal of Nuclear Medicine. 64(12). 1880–1888. 5 indexed citations
13.
Wang, Yirong, Lei Li, Juntao Li, et al.. (2023). 3D directional gradient L norm minimization guided limited-view reconstruction in a dual-panel positron emission mammography. Computers in Biology and Medicine. 161. 107010–107010.
14.
Kang, Fei, et al.. (2022). Painted radioluminescence imaging with radioluminescent nanophosphors. Applied Physics Letters. 121(23).
15.
Wang, Jingyi, Xing Lv, Guiyu Li, et al.. (2022). Establishment and Optimization of Radiomics Algorithms for Prediction of KRAS Gene Mutation by Integration of NSCLC Gene Mutation Mutual Exclusion Information. Frontiers in Pharmacology. 13. 862581–862581. 10 indexed citations
16.
Zhou, Zijian, Hongzhang Deng, Weijing Yang, et al.. (2020). Early stratification of radiotherapy response by activatable inflammation magnetic resonance imaging. Nature Communications. 11(1). 3032–3032. 77 indexed citations
17.
Xu, Xiaolong, Yi Liu, Yongheng Gao, et al.. (2018). Assessment of the Aging of the Brown Adipose Tissue by 1 8 F-FDG PET/CT Imaging in the Progeria Mouse Model Lmna −/−. Contrast Media & Molecular Imaging. 2018. 1–9. 8 indexed citations
18.
Qiang, Liang, et al.. (2018). An increased major vessel uptake by 18F-FDG-PET/CT in NIH criteria inactive patients with Takayasu's arteritis.. PubMed. 36 Suppl 111(2). 88–92. 10 indexed citations
19.
Song, Wei, Yu Li, Fei Kang, et al.. (2018). Comparison of 68Ga-PSMA-617 PET/CT and 99Tcm-MDP bone scintigraphy for bone metastases in prostate cancer. Zhonghua miniao waike zazhi. 39(10). 766–770. 1 indexed citations
20.
Kang, Fei, Weidong Yang, Xiaowei Ma, et al.. (2014). A direct comparison of tumor angiogenesis with 68Ga-labeled NGR and RGD peptides in HT-1080 tumor xenografts using microPET imaging. Amino Acids. 46(10). 2355–2364. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John A. Ronald Breakdown of academic impact, for papers by Vasileios Askoxylakis Breakdown of academic impact, for papers by Wendy Kelder Breakdown of academic impact, for papers by Michael J. Eblan Breakdown of academic impact, for papers by Carsten H. Nielsen Breakdown of academic impact, for papers by Antonello E. Spinelli Breakdown of academic impact, for papers by Everett J. Moding Breakdown of academic impact, for papers by Meenal Datta Breakdown of academic impact, for papers by Jane Sosabowski Breakdown of academic impact, for papers by Jianwu Xie
Rankless by CCL
2026